Irfan A Qureshi
Overview
Explore the profile of Irfan A Qureshi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1657
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial
Andrews J, Paganoni S, Macklin E, Chibnik L, Quintana M, Saville B, et al.
JAMA Neurol
. 2025 Mar;
PMID: 40067754
Importance: Myeloperoxidase is one of the most abundant peroxidase enzymes in activated myeloid cells. Myeloperoxidase inhibitors may have a clinical benefit in amyotrophic lateral sclerosis (ALS) by slowing neurodegeneration via...
2.
Petrozziello T, Jalali Motlagh N, Monsanto R, Lei D, Murcar M, Penney E, et al.
CNS Neurosci Ther
. 2024 Nov;
30(11):e70109.
PMID: 39500625
Aims: Although the genetic locus of X-linked dystonia parkinsonism (XDP), a neurodegenerative disease endemic in the Philippines, is well-characterized, the exact mechanisms leading to neuronal loss are not yet fully...
3.
Pfitzer J, Pinky P, Perman S, Redmon E, Cmelak L, Suppiramaniam V, et al.
J Neurochem
. 2024 Aug;
169(1):e16215.
PMID: 39214859
Alzheimer's disease (AD) is a neurodegenerative condition in which clinical symptoms are highly correlated with the loss of glutamatergic synapses. While later stages of AD are associated with markedly decreased...
4.
Petrozziello T, Motlagh N, Monsanto R, Lei D, Murcar M, Penney E, et al.
medRxiv
. 2024 Jul;
PMID: 38978657
Highlights: MPO activity is increased in XDP post-mortem prefrontal cortex.MPO activity is increased in cellular models of XDP.MPO increases reactive oxygen species (ROS) in vitro.Inhibiting MPO mitigates ROS in XDP.The...
5.
Woodhead J, Gebremichael Y, Macwan J, Qureshi I, Bertz R, Wirtz V, et al.
Xenobiotica
. 2024 Jun;
54(7):401-410.
PMID: 38874513
The novel myeloperoxidase inhibitor verdiperstat was developed as a treatment for neuroinflammatory and neurodegenerative diseases. During development, a computational prediction of verdiperstat liver safety was performed using DILIsym v8A, a...
6.
Neel D, Baselga-Garriga C, Benson M, Keegan M, Chase M, DAgostino D, et al.
Muscle Nerve
. 2024 Jun;
70(2):232-239.
PMID: 38842106
Introduction/aims: Expanded access (EA) is a Food and Drug Administration-regulated pathway to provide access to investigational products (IPs) to individuals with serious diseases who are ineligible for clinical trials. The...
7.
Shadyab A, LaCroix A, Matthews G, Bennett D, Shadyab A, Tan D, et al.
Alzheimers Dement (N Y)
. 2022 Mar;
8(1):e12265.
PMID: 35310528
Introduction: The reporting of approaches facilitating the most efficient and timely recruitment of Alzheimer's disease (AD) patients into pharmacologic trials is fundamental to much-needed therapeutic progress. Methods: T2 Protect AD...
8.
9.
Longo D, Shoda L, Howell B, Coric V, Berman R, Qureshi I
Toxicol Sci
. 2020 Feb;
175(2):292-300.
PMID: 32040174
For patients with amyotrophic lateral sclerosis who take oral riluzole tablets, approximately 50% experience alanine transaminase (ALT) levels above upper limit of normal (ULN), 8% above 3× ULN, and 2%...
10.
Ezzati A, Harvey D, Habeck C, Golzar A, Qureshi I, Zammit A, et al.
J Alzheimers Dis
. 2019 Dec;
73(3):1211-1219.
PMID: 31884486
Background: Amyloid-β positivity (Aβ+) based on PET imaging is part of the enrollment criteria for many of the clinical trials of Alzheimer's disease (AD), particularly in trials for amyloid-targeted therapy....